Efficacy and safety of probiotics in the induction and maintenance of inflammatory bowel disease remission: a systematic review and meta-analysis
Year: 2021
Type: review
Study designs: Systematic Review, Meta-Analysis
Abstract: BACKGROUND: Probiotics have been widely used in the treatment of inflammatory bowel disease (IBD) due to their special conditioning effects on the intestinal flora, but their efficacy in inducing and maintaining remission is still controversial. In the present study, we analyzed randomized controlled trials (RCTs) on the treatment of probiotics in IBD to systematically evaluate the efficacy of probiotics on the induction and maintenance of remission of IBD. METHODS: PubMed, Cochrane Central Register of Controlled Trials, Embase, Web of Science, Chinese Journal Full-text Database, Chinese Biomedical Literature Database, Wanfang, and Weipu databases were searched for RCTs on the treatment of probiotics in IBD induction and/or maintenance of remission. Two researchers independently extracted literature data and cross-checked the extracted data. The Cochrane bias risk assessment tool and the Jadad score were used to evaluate the quality of the literature. RevMan 5.20 software was used for the meta-analysis. RESULTS: A total of ten RCTs were included, which included 777 patients with ulcerative colitis (UC) and Crohn's disease (CD). Meta-analysis showed that there was no significant difference between the clinical recurrence rate of probiotics in the CD remission phase and the control group [relative risk (RR): 0.80, 95% confidence interval (CI): 0.61-1.06, P=0.12]. The clinical recurrence rate of UC in remission phase, the efficacy of probiotics compared with control group were not significantly different (RR: 1.07, 95% CI: 0.80-1.42, P=0.65). The induction remission rate of UC during the active phase, the efficacy of probiotics is better than that of the control group (RR: 1.47, 95% CI: 1.09-1.98, P=0.01). DISCUSSION: In the present study, a systematic analysis of the efficacy of probiotics in CD and UC found that probiotics can induce remission during the active period of UC, but have no obvious therapeutic advantage in maintaining CD and UC remission.
Source: Annals of Palliative Medicine
DOI: 10.21037/apm-21-2996
Authors: Mingshi Chen, Yan Feng, Wanli Liu
Language: English
Topic: Inflammatory Bowel Disease
Subfield: Gastroenterology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W3214752435